blue 3D waveform render

Investors

Welcome to the iCAD Investors page.

iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit www.icadmed.com

2025 Investor Deck

Sign up to receive Investor Alerts.

Subscribe to receive investor alerts from iCAD, Inc.

Press Releases

March 19, 2025

iCAD Reports Financial Results for Fourth Quarter and Fiscal Year Ended December 31, 2024

NASHUA, N.H. – March 19, 2025 – iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”) a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the fourth quarter and full…

March 11, 2025

iCAD to Report Fourth Quarter and Full Year 2024 Financial Results on March 19, 2025

NASHUA, N.H., March 11, 2025 — iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the fourth quarter and year ended December 31, 2024, after market close, and host a conference call at 4:30 PM Eastern Time…

March 5, 2025

iCAD and RamSoft Announce Partnership to Deliver ProFound AI-Powered Mammography Solutions Across North America

NASHUA, NH, and TORONTO, CANADA, March 05, 2025 — iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and RamSoft®, a global leader in cloud-based RIS/PACS radiology solutions for imaging centers and providers, today announced a new strategic commercial preferred distributor and integration partnership across…

Recent Events & Earning Calls

009 – Graph Created with Sketch.

Investor Relations

Investor Contact:
John Nesbett | Rosalyn Christian
IMS Investor Relations
icad@imsinvestorrelations.com
Megaphone

Media Inquiries